A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ZUMA-2
- Sponsors Kite Pharma
- 03 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jul 2018.
- 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
- 07 Oct 2016 According to a Kite Pharma media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) annual congress.